Law360, New York (May 30, 2008, 12:00 AM ET) -- Merck & Co Inc. crafted its $4.85 billion Vioxx settlement despite winning 12 of 17 jury verdicts over the painkiller. Although appeals courts have recently overturned two of those verdicts, lowered damages in a third case and rejected medical monitoring claims in still another, many legal pundits agree with Merck that settling before the appellate rulings was ultimately the right decision.
Settling plaintiffs have until July 1 to submit packages to support their claims. About 44,000 of 47,000 eligible Vioxx claimants, or 93%, have enrolled in...
Vioxx Deal Holds Up Even After Appeals Wins: Experts
To view the full article, take a free trial now.
